NKGen Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Cash & Equivalents	0.28	0.12	0.35
Cash & Cash Equivalents	0.28	0.12	0.35
Cash Growth	135.90%	-66.67%	-
Receivables	0	0.03	0
Other Current Assets	1.65	0.2	0.26
Total Current Assets	1.93	0.35	0.61
Property, Plant & Equipment	14.46	15.88	17.37
Goodwill and Intangibles	0.09	0.1	0.09
Total Long-Term Assets	14.55	15.98	17.46
Total Assets	16.48	16.33	18.07
Accounts Payable	13.4	2.65	2.2
Current Debt	9.99	12.03	51.61
Other Current Liabilities	16.07	0.06	1.93
Total Current Liabilities	39.45	14.74	55.74
Long-Term Debt	9.93	0	0.36
Other Long-Term Liabilities	25.79	0.03	0.02
Total Long-Term Liabilities	35.72	0.03	0.38
Total Liabilities	75.17	14.77	56.12
Total Debt	19.92	12.03	51.97
Debt Growth	65.54%	-76.84%	-
Retained Earnings	-162.13	-79.18	-52.42
Shareholders' Equity	-58.69	1.56	-38.05
Net Cash / Debt	-19.65	-11.92	-51.62
Net Cash Per Share	-1.27	-1.87	-3.62
Working Capital	-37.52	-14.39	-55.13
Book Value Per Share	-3.81	0.25	-2.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).